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Introduction
Rather than being slowly eroded and destroyed, countless numbers
of varied forms of life adapt to the diverse aspects of an ever changing
environment. However, the amount of variation is maintained at a
practical optimum, as too much variation would make the population
ill-adapted in a stable environment, while too little variation would
render it unable to adapt to environmental stresses. This principle is
perhaps well exemplified by a phenomenon described for microbial
cells termed ‘‘persistence’’ where in the face of antibiotics bacterial
populations avoid extinction by harboring a subpopulation of drug-
insensitive dormant cells. Although this phenomenon poses a major
obstacle for the treatment of infectious diseases, persistence has been
underappreciated for some time as a mechanism for bacteria to evade
antibiotics. But the mechanisms of bacterial persistence are becoming
clearer and so are ways to combat them. This article highlights the
phenomenon of survival and persistence in cells as diverse as microbial
and human and summarizes the recent advances that have taken us
one step closer to understanding what persistence is all about.
Microbial ‘‘Persister’’ Cells
In the early 1940s, it was only appropriate for Joseph Bigger to
refer to a small subpopulation of bacterial cells that survived killing
by penicillin, as ‘‘persisters’’ [1]. These small numbers of cells were
then proposed to be dormant and nongrowing phenotypic variants
of the general cell population [2,3]. This theory of ‘‘persisters’’ has
since been established in various bacterial populations. However,
more recently the existence of a small cell subpopulation that can
remain viable at high concentrations of an antifungal agent was
described for the fungal pathogen Candida albicans [4–6].
Therefore, it has become clear that the ability to avoid killing is
a key characteristic common to all microbial persisters that are not
mutants, but rather phenotypic variants that can survive
antimicrobial treatment. However, unlike drug resistance, drug
tolerance appears to be a transient and reversible physiological
state in a small subpopulation of genetically identical cells [7,8].
When the antimicrobial agent is removed, these persisting
microbial cells not only resume growth, but their progeny is
sensitive to the antimicrobial agent (Figure 1) [7,8].
Formation of Drug Tolerant Persisters
Persisters have been described to arise spontaneously on the
basis of random stochastic events [2,3,9]. Stochasticity can be
advantageous in providing flexibility for the cells to adapt to
fluctuating environments and sudden stresses and, therefore,
stochastic mechanisms are thought to lead to the emergence of
phenotypically distinct subgroups within isogenic cell populations
[9]. However, defined inducible mechanisms have been recently
identified to play a role in persister cell formation [10].
Quiescence and Biofilms
Recent findings from studies examining the rate of bacterial
persister-cell formation over time showed that the highest
frequency (,1%) occurs in the nongrowing stationary phase
[5]. Interestingly, when the culture was kept in early exponential
phase by repeated regrowth, persister cells disappeared, indicat-
ing that persisters are preformed rather than produced in
response to stress [5]. Furthermore, gene expression studies
demonstrated the downregulation of transcription of genes
involved in energy production and nonessential functions
concomitant with upregulation in genes associated with cellular
arrest [2]. These findings are consistent with the description of
persister cells as being dormant, a transient state of existence that
would impede the ability of drugs to corrupt their target
molecules in the microbial cell [7]. In that respect, entry into
quiescence is advantageous; however, it is more beneficial for a
cell to be a dividing cell than a dormant cell. Therefore, it is more
likely that the optimal cell strategy is not to enter into persistence,
suggesting that the persister state is an altruistic behavior to
ensure the continuation of the population.
The simplest strategy to trigger entry into dormancy would be
to overproduce proteins or toxins that inhibit cellular processes
and growth [3,11]. One such identified factor is the high
persistence gene hipA, which encodes a toxin (HipA) that inhibits
translation in Escherichia coli. This toxin was identified to be
implicated in forming persisters because its overexpression
increased the frequency of persistence by 10,000-fold and resulted
in drug tolerance [12]. HipA is normally neutralized by HipB, a
transcription repressor that counteracts HipA by attaching to it
preventing it from shutting down protein production and,
therefore, hipBA has been categorized as a toxin/antitoxin (TA)
module [11,12]. Recently, through extensive studies including
structural analyses, Schumacher et al. [12] identified HipA to be a
protein kinase that phosphorylates the translation factor EF-Tu.
These findings demonstrating that HipA bound the EF-Tu peptide
supported the hypothesis that HipA mediates persistence by
phosphorylating one or more target proteins. On the basis of these
new insights into the mechanisms by which HipA mediates
persistence, the authors suggested that inhibitors that specifically
target the substrate-binding sites of HipA may prove effective
against persistence.
Perhaps, the best defined mechanism by which persister bacterial
cells arise comes from the fact that DNA damage induces one or
more components of the protective SOS stress response, a signaling
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E. coli, exposure to a DNA-damaging antibiotic triggered the gene
encoding a small membrane-acting peptide TisB, which decreases
proton motive force and ATP levels suggesting that TisB protein may
induce dormancy by shutting down cell metabolism [14]. These
speculations were substantiated by the findings demonstrating that
deletion of the tisB gene resulted in decreased frequency of persisters
tolerant to DNA-damaging antibiotic [14]. Interestingly, although
overexpression of tisB resulted in cell death, minor overproduction of
the peptide induced persister formation suggesting that induction of
TisB is involved in the production of multidrug tolerant cells, in turn
identifying tisB as a persister gene [14]. Combined, these observations
are in accordance with the perception that dormancy and SOS
response represent strategies of cell survival.
Persister cells are highly enriched in biofilms, which are
complex and highly organized surface-attached communities of
microbes embedded in a polymeric matrix [8,15]. Biofilms form
on abiotic surfaces and host tissue and are responsible for
infections of indwelling medical devices. It is estimated that over
65% of all infections are biofilm-associated, which tend to be
difficult to eradicate because of enhanced resistance to antimicro-
bials [2,16]. The biofilm environment is advantageous to the
microbial populations, however, when nutrients become limited
metabolic dormancy becomes the viable option [8]. In a clinical
setting, when most cells in a biofilm are readily killed by low
concentrations of antibiotics, the small metabolically dormant
phenotypes progress to become tolerant persister cells. By virtue of
their dormancy, this subpopulation of cells confer benefits to the
general cell population and are in turn responsible for the high
tolerance of bacterial biofilms to antimicrobial agents [3,7].
Persisters are formed by all bacterial species studied and are
present at 0.1%–1% in the biofilms of Pseudomonas aeruginosa, E. coli,
and Staphylococcus aureus [17]. Recently, the existence of a small cell
subpopulation that can remain viable at high concentrations of
antifungal agent has been described in fungal biofilms, specifically
for the human pathogen C. albicans [4,6]. Clinically, candidal
infections may resolve upon antifungal therapy but often remain
recalcitrant to treatment. In a recent study, on the basis of
tolerance to high doses of an antifungal agent, invariably all C.
albicans isolates recovered from nonresolving infections appeared to
be high-persister variants. Similar to bacteria, C. albicans forms
adherent biofilms, which are essentially recalcitrant to antifungals
[16,18]. The mechanism of C. albicans biofilm antifungal resistance
remains largely unknown; however, biofilms have been described
to exhibit a biphasic killing pattern in response to antimicrobial
agents, indicating that a subpopulation of highly tolerant cells
existed [6,7]. Interestingly, reinoculation of surviving cells
produced a new biofilm with a new subpopulation of persisters.
These observations suggest that C. albicans persisters, analogous to
their bacterial counterparts, are not mutants but phenotypic
variants and that attachment to a surface is what initiates
dormancy that leads to the formation of persisters [5,6].
Cancer Persister Cells
Similar to the obstacle in treatment of patients that develop
resistance to antimicrobials, acquisition of resistance to anticancer
drugs is a major problem in cancer therapy. Most treatments, even
ones that work, fail over time because tumor cells become
resistant. Different mechanisms of resistance have been described
for cancer cells such as modification of drug target and active
extrusion of drugs by efflux pumps and, therefore, it was largely
assumed that random gene changes confer resistance to drugs
[19]. However, this does not explain an increasingly observed
phenomenon in cancer chemotherapy; ‘‘retreatment response’’
[20,21]. In this model, it is proposed that once a small number of
cells that survive exposure to drugs that killed the majority of the
cells are given a ‘‘drug holiday,’’ they eventually regain their
sensitivity to the drug [22]. These observations indicate that
acquired resistance to cancer drugs may not necessarily result from
stable genetic mutations but may also involve a reversible ‘‘drug-
tolerant’’ state [22,23].
In a recent study by Sharma et al. [22], drug-sensitive cells were
treated with antitumor drugs at concentrations exceeding 100 times
the established IC50 values. Following three rounds of 72-h
treatments, the authors consistently detected a small subpopulation
of reversibly ‘‘drug-tolerant’’ cells demonstrating .100-fold reduced
drug sensitivity. Further analyses demonstrated that these cells
maintained viability via engagement of insulin-like growth factor 1
(IGF1) receptor signaling and an altered chromatin state and
treatment with IGF1 receptor inhibitors or chromatin-modifying
agents selectively ablated the drug-tolerant subpopulation
Cancer-initiating cells are proposed as a potential resistant
subpopulation because of their ability to escape the effect of drug
treatment by becoming quiescent [24]. This transient drug-
tolerant state could provide a mechanism that allows a small
subpopulation of tumor cells to withstand an initial destructive
attack of drug to enable their survival, until more permanent
resistance mechanisms can be established [22]. Intriguingly, this
transient ability to endure anticancer drugs was recently reported
to be highly reminiscent of the drug-tolerant microbial ‘‘persister’’
subpopulations [22,25]. In that sense, it is plausible to regard slow-
growing cancerous cells in highly proliferating tumors to be
analogous to microbial persister cells in biofilm (Figure 1).
Figure 1. Progression of persister cell development and
enhanced drug tolerance.
doi:10.1371/journal.ppat.1002121.g001
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Whether microbial or human in nature, it appears that cells have
evolved analogous redundant strategies where the function of survival
is assigned to a small dormant subpopulation of cells within a more
rapidly proliferating population. With most of the currently available
chemotherapeutic agents targeting exponentially growing cells, our
therapeutic arsenal is ineffective in eradicating these dormant
persister cells. Coupled with the increasing emergence of drug
resistanceandfailureoftherapiesdespite ourmedical advances,it has
become critical to develop novel classes of drugs. The prospect that
persisters are responsible for the persistence of chronic infections and,
more gravely, recalcitrance of disseminating cancers have identified
these culprit cells as viable targets for new therapies. However, such
discoveries rely heavily on the depth of our understanding the nature
of these intriguing cells, which would provide us with fundamental
insights into the mechanisms involved in the development of drug
tolerance. Inopportunely, their transient nature and low abundance,
has impeded experimental advancements to elucidate the dynamics
of the formation of these specialized cells that neither die nor grow.
Nevertheless, the recent unearthing of an inherent tactical approach
shared by diverse cellular insurgents will undoubtedly herald a new
era of research into the new field of ‘‘persisters.’’
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